September 2024
Moderna’s Mpox Vaccine Shows Superior Efficacy in Preclinical Study Compared to Approved Version
Moderna, Mpox vaccine, Preclinical study, Superior efficacy, Approved version
Astellas Gene Therapies to Close South San Francisco Manufacturing Facility
Astellas Gene Therapies, South San Francisco, manufacturing facility closure, gene therapy, biotech layoffs
ArsenalBio Secures $325M Funding to Advance Programmable CAR-T Therapies
ArsenalBio, CAR-T therapies, biotech funding, programmable cell therapies, solid tumors, Regeneron, BMS
Lilly and Haya Therapeutics Collaborate in $1 Billion Deal to Explore ‘Dark Genome’ for Obesity Treatments
Lilly, Haya Therapeutics, obesity, dark genome, RNA-based drug targets, biotech deal
ProKidney Streamlines Phase 3 Program to Expedite U.S. Approval of Rilparencel for Chronic Kidney Disease
ProKidney, rilparencel, chronic kidney disease, CKD, cell therapy, RMAT designation, FDA approval, Phase 3 trial
Athira Pharma’s Stock Plummets Following Disappointing Alzheimer’s Drug Trial Results
Athira Pharma, Alzheimer’s disease, fosgonimeton, LIFT-AD study, stock crash
Novartis Expands Radioligand Therapy Production with Two New US Facilities
Novartis, radioligand therapy, RLT, cancer treatment, manufacturing facilities, US expansion
BioAge Labs Files for IPO to Advance Obesity Treatment Candidate
BioAge Labs, IPO, obesity treatment, weight loss drugs, azelaprag, Eli Lilly, cardiometabolic biotech
Fenebrutinib Shows Promising Results in Relapsing Multiple Sclerosis Treatment
Fenebrutinib, Relapsing Multiple Sclerosis, BTK Inhibitor, Roche, Clinical Trials
Pfizer and Valneva Report Strong Immune Responses from Second Lyme Disease Vaccine Booster
Lyme disease, vaccine, Pfizer, Valneva, VLA15, booster, immune response, Phase 2 trials, FDA submission